Technologies
PDF


WARF: P08294US

Novel Antiviral Peptides Against Influenza Virus


INVENTORS -

Stacey Schultz-Cherry, Curtis Brandt, Jeremy Jones

The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in developing truncated versions of the EB peptide that can be used to prevent or treat influenza viral infections.
OVERVIEWInfluenza viruses cause morbidity and mortality worldwide. In the United States, influenza is responsible for approximately 200,000 hospitalizations and 36,000 deaths each year.

Two classes of antiviral drugs are currently approved to treat influenza. Adamantine derivatives prevent the virus from uncoating and releasing its genetic material into a cell. Neuraminidase inhibitors, on the other hand, prevent virus particles from leaving infected host cells and infecting new cells. However, viruses that are resistant to both classes of antivirals are emerging. New types of antiviral drugs are needed for the treatment and control of influenza.

UW-Madison researchers previously described a 20 amino acid peptide known as EB that can be used to enhance immune response to influenza vaccines (see WARF reference number P08262US). EB induces influenza viral particles to aggregate, preventing binding and uptake by epithelial cells. This same property also allows enhanced recognition by antigen presenting cells, leading to enhanced immunogenicity.
THE INVENTIONUW-Madison researchers now have developed truncated versions of the EB peptide that can be used to prevent or treat influenza viral infections. These shorter peptides exhibit antiviral activity against influenza viruses that is comparable to or better than that of EB. Like EB, they inhibit the attachment of influenza virus to host cells, preventing viral infection. However, some of these shorter peptides likely work through a different mechanism than EB. 
 
APPLICATIONS
  • Prevention or treatment of influenza virus infection
KEY BENEFITS
  • Less expensive to produce than the 20 amino acid form of EB
  • Easier to delivery systemically than the longer version of EB
  • Capable of inhibiting viral hemagglutination (a measure of the number of viral particles) by more than 90 percent
     
ADDITIONAL INFORMATION
For More Information About the Inventors
Related Intellectual Property
Publications
  • Jones J.C., Turpin E.A., Bultmann H., Brandt C.R. and Schultz-Cherry S. 2006. Inhibition of Influenza Virus Infection by a Novel Antiviral Peptide That Targets Viral Attachment to Cells. J. Virol. 80, 11960-11967.
Contact Information
For current licensing status, please contact Andy DeTienne at adetienne@warf.org or 608-960-9857.
The WARF Advantage

WARF: A Leader in Technology Transfer Since 1925
Since its founding as a private, nonprofit affiliate of the University of Wisconsin–Madison, WARF has provided patent and licensing services to UW–Madison and worked with commercial partners to transform university research into products that benefit society. WARF intellectual property managers and licensing staff members are leaders in the field of university-based technology transfer. They are familiar with the intricacies of patenting, have worked with researchers in relevant disciplines, understand industries and markets, and have negotiated innovative licensing strategies to meet the individual needs of business clients.

The University of Wisconsin and WARF –
A Single Location to Accelerate Translational Development of New Drugs

UW–Madison has the integrative capabilities to complete many key components of the drug development cycle, from discovery through clinical trials. As one of the top research universities in the world, and one of the two best-funded universities for research in the country, UW–Madison offers state-of-the-art facilities unmatched by most public universities.

These include the Small Molecule Screening Facility at the UW Comprehensive Cancer Center; the Zeeh Pharmaceutical Experiment Station, which provides consulting and laboratory services for developing formulations and studying solubility, stability and more; the Waisman Clinical Biomanufacturing Facility; the Wisconsin Institute for Medical Research, which provides UW–Madison with a complete translational research facility; and the innovative, interdisciplinary Wisconsin Institutes for Discovery, home to the private, nonprofit Morgridge Institute for Research and its public twin, WID, part of the university's graduate school. The highly qualified experts at these facilities are ready to work with you to create a library of candidates for drug development.